DelveInsight’s, “Tezacaftor (VX-661) + Ivacaftor, Launch Insights, 2017” report provides comprehensive insights about the Tezacaftor (VX-661) + Ivacaftor's launch. The report covers all the indications for which the Tezacaftor (VX-661) + Ivacaftor is being developed and also provides the competitive landscape for the major indications. The report further includes patent details, forecasted sales till 2022 and post launch market positioning.
The report will provide a clear picture of market positioning of the upcoming launch of Tezacaftor (VX-661) + Ivacaftor and will also provide the insight about how Tezacaftor (VX-661) + Ivacaftor will evolve in the market as well as within its respective class.Report provides detailed information of clinical trials that have been or are being conducted for this product. Analysis and Insightful information around the clinical trials is provided by assessment of the trial results.
Attribute analysis carried out by our analysts helps in understanding how the upcoming launch scores itself in comparison to other competitors (both marketed and pipeline). The scoring and analysis has been based upon scrutinizing data from all key clinical trials for the product. A head to head comparison with marketed products if available is scanned thoroughly. Further, analyzing data of other competitors with regards to the product also assists in proper scoring of the product in its space.
The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by DelveInsight team of industry experts. Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.
• Detailed product description including its chemical properties, molecule type and mechanism of action • Detailed description of non-clinical and clinical studies for all the indications • Patent expiry analysis of the drug along with other competitors in the market • Forecasted sales till 2022 • Tezacaftor (VX-661) + Ivacaftor market positioning analysis • Tezacaftor (VX-661) + Ivacaftor class share evolution